Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features

PLoS ONE

Volumn 3, Issue 4, 2008, Pages

  Sato, Fumiaki ^a,b,g   Jin, Zhe ^a,b   Schulmann, Karsten ^b,c   Wang, Jean ^a   Greenwald, Bruce D ^b   Ito, Tetsuo ^a,b   Kan, Takatsugu ^a,b   Hamilton, James P ^a,b   Yang, Jian ^a,b   Paun, Bogdan ^a,b   David, Stefan ^a,b   Olaru, Alexandru ^a,b   Cheng, Yulan ^a,b   Mori, Yuriko ^a,b   Abraham, John M ^a,b   Yfantis, Harris G ^d   Wu, Tsung Teh ^e   Fredericksen, Mary B ^e   Wang, Kenneth K ^e   Canto, Marcia ^a   Romero, Yvonne ^e   Feng, Ziding ^f   Meltzer, Stephen J ^a,b   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d BALTIMORE VA MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P16; TRANSCRIPTION FACTOR RUNX3; TUMOR SUPPRESSOR PROTEIN;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SURVEILLANCE; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS RESECTION; FEMALE; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; POLYMERASE CHAIN REACTION; PREDICTION; PROTEIN METHYLATION; RISK ASSESSMENT; ROC CURVE; SAMPLING; SENSITIVITY AND SPECIFICITY; UNITED STATES; CELL DIFFERENTIATION; ENDOSCOPY; ESOPHAGUS TUMOR; GENETIC EPIGENESIS; METHODOLOGY; METHYLATION; PATHOLOGY; PRECANCER; REPRODUCIBILITY; RISK; TREATMENT OUTCOME;

BARRETT ESOPHAGUS; CELL DIFFERENTIATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDOSCOPY; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; HUMANS; METHYLATION; PRECANCEROUS CONDITIONS; REPRODUCIBILITY OF RESULTS; RISK; RISK ASSESSMENT; ROC CURVE; TREATMENT OUTCOME;

EID: 44849142186     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001890     Document Type: Article

References (48)

1. Cameron AJ (1998) Management of Barrett's esophagus. Mayo Clin Proc 73: 457-161.
2. Cossentino MJ, Wong RK (2003) Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis 14: 128-135.
3. Tannapfel A (2004) Molecular findings in Barrett's epithelium. Dig Dis 22: 126-133.
4. Sato F, Meltzer SJ (2006) CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106: 483-493.
5. Clark GW. Ireland AP, DeMeester TR (1996) Dysplasia in Barret's esophagus: diagnosis, surveillance and treament. Dig Dis 14: 213-227.
6. Bueau USC.(2006) Monthly Postcensal Resident Population, by single year of age, sex, race, and Hispanic origin. http://www.census.gov/popest/ national/asrh/2005_nat_res.html.
7. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129: 1825-1831.
8. Reid BJ, Haggitt RC, Rubill CE, Roth G, Surawicz CM, et al. (1988) Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19: 166-178.
9. Montgomery E, Goldblum JR, Greenson JK, Haber MM, Lamps LW, et al. (20011) Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32: 379-388.
10. Shaheer NJ, Inadomi JM, Overholt BF, Sharma P (2004) What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 53: 1736-1744.
11. Johnston MH. (2005) Technology insight: ablative techniques for Barrett's esophagus-current and emerging trends. Nat Clin Pract Gastroenterol Hepatol 2: 323-?30.
12. Cameron AJ, Carpenter HA (1997) Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 92: 586-591.
13. Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, et al. (2007) Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 102: 483-493.
14. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, et al. (2001) Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32: 368-378.
15. Schulmann K, Sterian A, Berki A, Yin J, Sato F, et al. (2005) Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24: 4138-4148.
16. Sato F, Shibata D, Harpaz N, Xu Y, Yin J, et al. (2002) Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 62:6820-6822.
17. Sato F, Harpaz N, Shibata D, Xu Y, Yin J, et al. (2002) Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 62: 1148-1151.
18. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, et al. (2000) Fields of aberrant CpG island hypermethylation in Barrette's esophagus and associated adenocarcinoma. Cancer Res 60: 5021-5026.
19. Sato F, Shimada Y, Selaru FM, Shibata D, Maeda M, et al. (2005) Prediction of survival in patients with esophageal carcinoma using artificial neural networks. Cancer 103: 1596-1605.
20. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG (1989) Barrett's esophaps: development of dysplasia and adenocarcinoma. Gastroenterology 96: 1249-1256.
21. Spechler SJ (2002) Clinical practice. Barrett's Esophagus. N Engl J Med 346: 836-842.
22. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr (1993) Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 105: 383-387: discussion 387-388.
23. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA (2002) Surveillance and survival in Barrett's adenocarcinomas a population-based study. Gastroenterology 122: 633-640.
24. Playford RJ (2002) Antagonist: endoscopic surveillance of patients with Barrett's oesophagus. Gut 51: 314-315.
25. Barr H (2002) Protagonist: endoscopic surveillance of patients with Barrett's oesophagus. Gut 51: 313-314.
26. Eisen GM, Baron TH, Dominitz JA, Faigel DO, Goldstein JL, et al. (2002) Complications of upper GI endoscopy. Gastrointest Endosc 55: 784-793.
27. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, et al. (1993) An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 105: 40-50.
28. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, et al. (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22: 106-109.
29. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, et al. (2003), Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9: 2912-2919.
30. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51: 797-802.
31. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, et al. (2005) CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 65: 828-834.
32. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, et al. (2001) Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61: 3410-3418.
33. Meltzer SJ, Yin J, Manin B, Rhyu MG, Cottrell J, et al. (1994) Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res 54: 3379-3382.
34. Kondo Y, Issa JP (2004) Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 23: 29-39.
35. Zingg JM, Jones PA (1997) Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 18: 869-882.
36. Weston AP, Badr AS, Hassanein RS (1999) Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 94: 3413-3419.
37. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, et al. (1998) The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barret's esophagus. Am J Gastroenterol 93: 536-541.
38. Conio M, Blanchi S, Lapertosa G, Ferraris R, Sablich R, et al. (2003) Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 98: 1931-1939.
39. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, et al, (2000) The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 95: 3383-3387.
40. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, et al. (1999) Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 50: 23-26.
41. Takubo K, Arai T, Ishiguro S (2002) Patient presentation and pathologic diagnosis of superficial carcinoma of the esophagus: high-grade dysplasia and mucosal carcinoma from the Japanese standpoint. In: Imamura M, ed. Superficial Esophageal Neoplasm. Tokyo: Springer-Verlag. pp 141-147.
42. Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, et al. (2000) Gastric dysplasia: the Padova international classification. Am J Surg Pathol 24: 167-176.
43. Eaden J, Abrams K, McKay H, Denley H, Mayberry J (2001) Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 194: 152-157.
44. Rudolph RE, Vaughan TL, Storer B (2000) Segment Length and Risk for Neoplastic Progression in Patients with Barrett Esophagus. Ann Intern Med 133: 748.
45. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, et al. (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061.
46. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ (2001) Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 96: 3071-3083.
47. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, et al. (2001) Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96: 2839-2848.
48. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, et al. (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55: 1000-1006.